Evaluating only Organovo’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Market timing.
Key Events Timeline
FOUNDING
Gabor Forgacs co-founds Organovo in San Diego to commercialize bioprinting technology from University of Missouri research.
FUNDING
Organovo goes public on NASDAQ raising ~$35M; stock surges on bioprinted liver tissue announcements.
PRODUCT LAUNCH
ExVive3D liver tissue commercial launch disappoints; pharmaceutical clients cancel or do not renew contracts citing performance gaps.
SHUTDOWN
CEO Taylor Crouch announces exit from bioprinting; company pivots to acquire Tarveda Therapeutics, abandoning core mission.
Full Analysis
Free · no account needed
Documented cause
Organovo, founded by Gabor Forgacs at UC San Diego, raised over $140M on NASDAQ (ONVO) promising bioprinted human liver and kidney tissues for drug testing. By 2019, after burning through cash with no FDA-approved bioprinted product and pharmaceutical customers failing to renew contracts, CEO Taylor Crouch announced the company would exit the bioprinting business entirely and pivot to an unrelated therapeutic acquisition, effectively killing the original mission.
Lesson
“Deep-tech biotech needs realistic commercialization timelines; pivot before cash runs out, not after.”